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In the present perspective it is described the advances and real possibilities of 1,3-dipolar 
cycloadditions as key step in the total synthesis of virus inhibitors. Azides, nitrones, and 
azomethine ylides are the most appropriate 1,3-dipoles for the synthesis of privileged structures 10 
with the highest biological response against viruses.  
1. Introduction 
Newly emerging viral infections represent the major threat to 
human health. If we analyze the data concerning only the 
killed people by the Influenza pandemics during the last 15 
century, we notice that this number goes beyond the deaths 
caused by other natural or man-made disasters. World Human 
Organisation (WHO)1 alerts on the viral outbreaks announcing 
the spreading ways of the virus urging all governments to step 
up surveillance. 20 
 Apart of the three more extended global virus infections 
namely human immunodeficiency virus (HIV, 35 millions 
approximately), hepatitis C virus (HCV, more than 190 
millions) and influenza A and B viruses, ebola, Marburg, 
dengue, yellow fever, nipah, enterovirus 71 and oncoviruses 25 
are the most dangerous viruses causing many human 
fatalities.2 An additional drawback of these microorganisms is 
their fast mutation rates because a small genetic variation in 
an, a priori, inoffensive virus can originate a new strand with 
increased capacity to cause disease (virus with increased 30 
virulence). 
 The vaccine development is an extremely effective strategy 
to protect people from specific virus infections. However, an 
appropriate vaccine cannot be developed before a virus can be 
replicated in sufficient quantities to manufacture it. In fact, 35 
vaccines are very effective on stable virus but difficult to 
apply to rapidly mutagenic viruses such as influenza, HCV, 
etc. In this last situation, and obviously when the patient has 
already been infected, is when antiviral drugs became crucial. 
An antiviral drug does not kill the virus, but acts by 40 
interfering one step of the viral replication process. This 
lowering in the replication frequency allows the body’s 
immune system to destroy the virus using many natural 
defences. 
 Researchers working on strategies for developing antivirals 45 
have tried to attack viruses at every stage of their life cycles, 
namely attachment to a host cell, replication of viral 
components, assembly of viral components into complete viral 
particles and release of viral particles able to infect new hosts 
cells. The present and the future of these antiviral tools has 50 
been reported since the pharmacological point of view of 
pathogenic specific drugs such as amantidine, Tamiflu®, and 
Relenza® or ribavirin and interferons targeted against 
influenza or hepatitis C viruses, respectively.3 Unfortunately, 
extensive data on their efficacy are not available and recent 55 
reports of drug resistance in patients infected with, for 
example, H5N1 raise serious concerns.4 So, new broad-
spectrum antivirals must be developed because the cost and 
the risk to a rapid drug resistance of the antivirals targeted 
against single viruses are very elevated. 60 
 Genomics helps scientists to find targets at every viral stage 
and also provides crucial data for understanding the drug-
virus effective interaction. Closely, the organic synthetic 
chemists are dedicating many efforts to design and prepare 
potential drugs once targets have been identified. From all of 65 
the resources, methodologies, reactions, etc., put into service 
of the preparation of antiviral agents,5 1,3-dipolar 
cycloaddition (Hüisgen cycloadditions)6 constitute a powerful 
classical synthetic tool and one of the most productive fields 
in modern organic chemistry.7  70 
 The reaction between 1,3-dipoles and alkenes or alkynes is 
very versatile allowing the presence of many functional 
groups in both components, namely 1,3-dipole I and 
dipolarophile II (Scheme 1). Yields of heterocycles III are 
elevated with a few and easily removable impurities. The 75 
available precursors of dipole I can be, basically, divided in 
two groups: the allyl anion-type Ia such as nitrones, 
azomethine ylides, azomethine imines, carbonyl ylides and 
carbonyl imines, and the linear propargyl/allenyl anion-type 
Ib such as nitrile oxides, nitrile imines, nitrile ylides, 80 
diazoalkanes and azides (Figure 1). 
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Scheme 1. General 1,3-DCs of alkenes and alkynes. 
  
 This [2s+4s] addition is stereoconservative (suprafacial) 
and stereospecific, and the six π-electrons participate in a 
concerted or non-concerted reaction pathway controlled by the 5 
HOMO-LUMO interaction rules.7c,8 The results of this 
elevated stereocontrol is the responsible of the high diastereo 
and regioselectivity (and also enantioselectivity in asymmetric 
synthesis examples) achieved in an impressive number of 
heterocycles III.7,9 Another important feature of this 10 
transformation10,11 is that up to four stereogenic centres can be 
unambiguously generated in only one reaction step whether a 
diastereo- or enantioselective approach is performed. 
 The general interest of these broad series of cycloadducts 
III, as potential antiviral drugs,12 will be focussed on this 15 
perspective. For convenience, the examples will be classified 
on the basis of the involved 1,3-dipole, which are highlighted 
in a frame in the Figure 1. 
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Figure 1. Most important 1,3-dipoles in the synthesis of 
heterocycles III. 
 
2. Azides 
 25 
Organic azides 1 are readily available and potentially 
explosive compounds. Although the 1,3-DC between azides 1 
and alkynes 2 (also with nitriles)7d is known for years, they 
are extensively employed since 2001.11,13 The interest of this 
process was the transformation of the purely thermal 30 
procedure13 to a 1,3-DC catalysed by metal salts [mostly 
copper(I) salts], which dramatically accelerated the reaction 
even at room temperature (Scheme 2).14 Under these catalysed 
reaction conditions, the process becomes nearly solvent 
insensitive, it shows an extremely high tolerance of functional 35 
groups and affords 1,2,3-triazoles 3 in excellent chemical 
yields with few by-products.15 1,2,3-Triazoles are exceedingly 
stable to acidic and basic hydrolysis as well as severe 
reductive/oxidative conditions, and also capable of active 
participation in hydrogen bonding as well as dipole-dipole and 40 
π-stacking interactions. The other important feature concerns 
the high regioselectivity achieved (1,4 addition over 1,5-
addition) (Scheme 2b), unlike the thermal procedure that 
exhibits very poor regioselectivity (Scheme 2a). The resulting 
1,2,3-triazole moiety16 is a likely candidate for small molecule 45 
drugs compatible with the side chain of all of the amino acids 
and the molecular dimensions of these heterocycles are 
somewhat similar to the amide bonds in terms of distance and 
planarity. These last two properties of 3 are closely related 
with the successful interaction with enzymes or even DNA or 50 
RNA strands of the viruses in order to deter their 
proliferation. 
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Scheme 2. Cu-catalysed versus thermal 1,3-DC of azides and 55 
alkynes. 
 
 Many works focused on this 1,3-DC of azides and alkynes 
had, unfortunately, not marked biological activity. The most 
productive results are shown as follows on the basis of the 60 
type of virus inhibited. 
 There is not vaccine or cure for HIV, and the most 
employed treatment consists of highly active antiretroviral 
therapy. Many derived compounds of AZT (a reverse 
transcriptase inhibitor) and others were prepared through a 65 
1,3-DC between organic azides and alkynes with the objective 
of decreasing the viral replication and lowering their 
cytotoxicity (Figure 2). Nucleosidic molecules 5-7 and 9, and 
the non-nucleosidic structures 8 and 10 are examples of 
triazole-containing entities able to inhibit HIV proliferation. 70 
One of the first contributions in this area was published in 
1989, but nucleoside 5 showed moderate activity in HIV-1 
infected cells.17 The same author used hydrazoic acid as 1,3-
dipole and a carbodiimide as dipolarophile, generated from 
AZT, for the elaboration of compound 6, which also exhibited 75 
moderate activity against HIV-1.18 The series of products 7 
were prepared and tested as antiviral HIV agents, the most 
active being R1 = But(Me)2Si-, R2, R4 = H, R3 = CONMe2.19 
Phosphasugar N-nucleoside derivatives were prepared to be 
antiviral agents but any data about biomedical studies was 80 
described.20 Compound 9 showed an interesting activity 
against wild type HIV-1 and mutant strains, which is 
comparable with other nucleoside reverse transcriptase 
inhibitors such as MKC-442.21 Molecules 5-9, as surrogates of 
AZT, function as analogues for thymidine and this means that 85 
AZT and its mimetics, have the same shape as it, and 
therefore it can be incorporated into the developing nucleic 
acid in place of a thymidine molecule. The phosphate group 
attached to thymidine or AZT forms a bond with the 3'-OH 
group of the preceding nucleotide in the developing DNA 90 
chain. When thymidine is incorporated into the DNA chain, 
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its 3' -OH becomes the binding site for the next nucleotide's 
phosphate group. However, AZT and its mimeics lack the -
OH functional group that is necessary to form a bond with the 
next nucleotide; in its place is an azido (-N3) group. Because 
the azido group cannot form a bond with a phosphate group, 5 
no additional nucleotides can be added once AZT is 
incorporated into the DNA chain. Hence, reverse transcription 
stops after AZT is incorporated.  
 The non-nucleosidic product 10 (obtained by a 
conventional 1,3-DC) revealed to be an important inhibitor of 10 
the wild type HIV1 (IC50 = 6 nM) and also of several mutant 
strains.22 This molecule inhibit certain proteases, which are 
enzymes used by the viruses to cleave nascent proteins needed 
for the final assembly of new virions, and their inhibition also 
prevent the viral replication. The authors observed that the 15 
incubation of the azide 11 and alkyne 12 in the presence of the 
HIV-1-PrSF-2WTQ74-Pr protease (henceforth simply denoted 
SF-2-Pr, 15 μM) in 2-morpholinomethanesulfonic acid (MES; 
0.1 M) NaCl (0.2 M) buffer solution at 23 ºC for 24 h, the 
acceleration of the reaction (ten fold) occurred enhancing the 20 
regioisomeric ratio in favour of the 1,4-isomer 10 (18:1). The 
target protease itself acted as a template for the reaction 
(Scheme 3) that forms its own inhibitor.23 Paragraph removed 
here.   
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Figure 2. Important inhibitors of HIV virus. 
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 A recent contribution demonstrated that compound 10 retains 
high affinity for both wild-type and PR6x multidrug resistant 
(MDR) protease viruses as the result of interactions with selected 
residues and maintenance of hydrogen bonding to main chain 35 
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atoms. Thus, compound 10 binds to the protease that promotes 
multidrug resistance, the triazole moiety forms a precise 
hydrogen bonding network and the carbamate accepts a hydrogen 
bond from the amide of Gly48. Both of these interactions feature 
a conserved element of protease structure. The 1,3-DC of 5 
modified starters 11 and 12 will also allow the evaluation of 
whether such changes improved the antiviral performance against 
newly appearing multidrug-resistant viruses.24  
 The employment of the catalysed 1,3-DC of azides and 
alkynes contributes to the formation of novel templates based on 10 
oligosaccharide25 or peptide26 clusters. The incorporation of 
several units of triazole derivatives on these natural or synthetic 
polymers is responsible of their increased binding affinity and 
antiviral activity against multiple strands of HIV-1. This strategy 
allows to optimise the size and nature of the substituents in both 15 
dipole and dipolarophile to achieve the best efficiency with the 
smallest structure. For example, the successful construction of the 
fully synthetic immunogens that contain novel oligosaccharide 
clusters has laid the foundation for further immunisation studies 
in animals to evaluate whether the vaccine candidates are able to 20 
elicit carbohydrate-specific neutralising antibodies against HIV,25 
constituting a very exciting research area. Particularly, it is 
known that sugar chains were crucial for high affinity binding to 
the antibody 2G12. This human monoclonal antibody potently 
and broadly neutralizes primary and T-cell line-adapted clade B 25 
strains of HIV-1 in a peripheral blood mononuclear cell-based 
assay and inhibits syncytium formation in the AA-2 cell line. 
 Worldwide extended influenza viruses caused seasonal 
epidemic. Vaccinations against influenza are usually given to 
people, the most common being trivalent influence vaccine 30 
(TIV). It contains purified and inactivated material for two 
influenza A viruses subtype and one influenza B strain. Spite of 
this advantage, several specific antiviral drugs have been 
designed to inhibit the most aggressive influenza virus types. The 
most active synthetic compound corresponded to the series of 35 
non-nucleosidic molecules 13, whose structure is very similar to 
zanamivir. In fact, compound 13 [R1 = CH(OH)C2H5, R2 = H) is 
almost as active as zanamivir against avian influenza virus (AIV) 
H5N1.27 In this work molecular modelling provided very reliable 
information about the binding model between inhibitors and 40 
neuraminidase, which was in a good agreement with the observed 
in vivo activity of the inhibitors. To better understand the activity 
discrepancy of synthesised new inhibitors and zanamivir, the 
study was based on the crystal structure of neuraminidase-
inhibitors derived from docking simulation. Whilst carboxylic 45 
acid group of zanamivir formed strong hydrogen bonds with two 
arginine residues (Arg118, Arg371) in the S1 region and five 
hydrogen bond interactions in S2 region through the guanidinyl 
moiety, inhibitor 13 [R1 = CH(OH)C2H5, R2 = H) moved up 
forming exclusively a hydrogen bond with residue Arg152 in the 50 
S2 region. Large substituents with different electronic properties 
of other molecules 13 could not be accommodated in the subsite 
S2, and hence the six membered ring flipped resulting in a drop 
of inhibitory activity.27 
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Figure 3. Compounds inhibitors of influenza virus. 
 
 The neuraminidase enzymes (also called sialidases) are 
glycoside hydrolase enzymes that promote the mobility of 60 
virus particles through the respiratory tract mucus and in the 
elution of virion progeny from the infected cell. In this line, 
multivalent 1,3,5-triazine or sialic acid containing-scaffolds 
have been designed incorporating structures 13, which have 
shown to have stable structures in solution and well suited for 65 
functionalisation with antiviral relevant ligands versus 
influenza viruses.28,29 
 Ribavirin and their analogues are widely used for treating 
HCV infections. Searching for a highest inhibition of the 
HCV and lowest cytotoxicity, 1,2,3-triazole derivative 70 
families such as 16 and 17 were prepared. Although the 
antiviral activity of their dibenzoylated surrogates was 
moderate, it was noticeable the high regioselectivity achieved 
with Cuº/CuSO4 couple (favouring the 1,4-regioisomer), and 
the reverse regioselectivity (favouring the 1,5-regioisomer) 75 
obtained when Cp*RuCl(PPh3)2 complex was employed. 
Protected β-azidoribose 14 reacted with alkynes 15 under a 
copper(I)-catalysed 1,3-DC affording triazoles 16 in very 
good yields and with total 1,4-regioselectivities (>99:1) 
(Scheme 4). Highest conversions and chemical yields were 80 
generated upon microwave radiation, in the presence of the 
above mentioned ruthenium catalyst, furnishing compound 17 
with a high 1,5:1,4 regioisomeric ratio (up to 97:3).30 
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Scheme 4. Regioselective synthesis of compounds 16 and 17. 
 
 There is currently substantial interest in the use of nucleic 
acids for modifying gene expression for therapeutic purposes. 
The lipid-conjugated oligonucleotides via 1,3-DC potentiates 90 
the cellular uptake of oligonucleotides and allows their 
intracellular delivery. These non-toxic lipid conjugates 18 
(Figure 4) efficiently inhibit HCV internal ribosome entry 
site-mediated translation in human hepatic cells. The specific 
target was the subdomain IIId of the mentioned internal 95 
ribosome entry site at the 5’ end of the viral RNA.31  
 This journal is © The Royal Society of Chemistry [year] Journal Name, [year], [vol], 00–00  |  5 
 Through a similar mechanism, oligonucleotides bearing the 
p-tolyl-group as substituent of the both oxygen atoms in 19 
afforded better interactions with the virus. In addition, this 
protecting group decreased notably their cytotoxicity. 
Particularly active were the newly synthesized compound 19 5 
bearing a 6-chloro-7-deazapurine or 2-amino-6-chloro-7-
deazapurine (Figure 4).32  
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Figure 4. Antivirals against HCV. 10 
 
 Less aggressive hepatitis B virus (HBV) has also been 
moderately inhibited by 1,2,3-triazoles 20 and 21 (Figure 5) 
obtained as cycloadducts by reaction of 1-propargyl 
pyrimidines with 5-azido-5-deoxyribofuranoside or 1-azido-1-15 
deoxytetra-O-acetylglucose. The most active structures were 
the pyrimidine derivatives rather than the pyridine analogues, 
obtained from 1-propargyl pyridinium salts. Presumably, this 
anti-HBV therapy was originated by inhibition of viral 
replication degrading HBV pregenomic RNA and message 20 
RNAs.33,34 
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Figure 5. Bioactive compounds against HBV. 
 25 
 Acyclonucleosides 22 and 23, with the alkylating chain of 
acyclovir, were prepared and evaluated against tuberculosis 
virus showing moderate activity.35,36 Carbonucleosides 24 
gave very low inhibition levels of small pox, vaccinia or 
cowpox viruses.37 However, 1,2,3-triazole carbanucleosides 30 
25 and more specifically iodide 26 (Figure 6) exhibited an 
elevated inhibitory potential against thymidine kynase 
varicella-zoster virus (TK+VZV).38 
 Another applications of 1,3-DC of azides and alkynes or 
alkenes concerns the construction of biomolecular prototypes. 35 
For example, it was observed that the degradation of the viral 
particles occurred during the 1,3-DC of the corresponding 
alkyne, and the azide derived from the icosahedral cowpea 
mosaic virus (CPMV). Molecules 27 (Figure 6) incorporate an 
aliphatic chain with a 1,2,3-triazol unit. This carbonous 40 
structure is bonded to the virus through an amino group of the 
native reactive lysines, and genetically inserted cysteines of 
the protein subunits arranged helically around genomic single 
RNA strand.39 This binding caused degradation or variation of 
the stability of the viral peptides, which has been considered 45 
of great interest for future investigations.39,40,41 
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 Although they are not considered antiviral agents, there are 
another contributions dealing with the synthesis of very 
interesting useful molecules for the study of biomolecular 
recognition, binding mecanisms, etc. For example, the 55 
synthesis of radiolabelled peptides (18F or 11C), incorporating 
1,2,3-triazole units, have been used as diagnostic agents, for 
example, as radiopharmaceuticals for several purposes, and 
also served as a vector to direct a small drug to the virus.42 As 
well, azides and alkynes are easily transformed in the 60 
corresponding 1,2,3-triazoles in the synthesis of ligands for 
the preparation of antiviral drugs,43 in the preparation of 
sensors on oligo- or poly(ethylene glycol) films on silicon 
surfaces, which possessed an structural portion capable of 
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being recognised by a biological specimen (included 
viruses),44 and finally, in the elaboration of cross-linked 
polymeric multilayers, interesting for the fields of directed 
drug delivery towards viruses and tissue engineering.45 
 5 
 
3. Nitrones 
 
Nitrones 28 or azomethine oxides were first prepared by 
Beckman in 1890. Their chemistry is hugely varied,46 but it is 10 
ultimately dominated by their use as 1,3-dipoles for 
cycloaddition reactions.7,47 The most common 1,3-DC 
involving nitrones, is the formation of isoxazolidines 3048 
using alkenes 29 as dipolarophiles (Scheme 5), although other 
different multiply bonded systems may also be used such as 15 
alkynes, allenes, isocyanates, nitriles, thiocarbonyls, etc. The 
isoxazolidine adduct 30 contains up to three new stereogenic 
centres and the reaction products can be predictable according 
to the experiences, results and frontier molecular orbital 
(FMO) theory.7c The E/Z-interconverting nitrones 28 reacted 20 
with electron-rich alkenes 29a through a first nitrone oxygen 
atom attack to the α-position of the electron-rich alkene, 
however, this oxygen atom react with the β-position of the 
electron-poor alkenes 29b (Scheme 5). Often, diastereomeric 
pairs of exo- and endo-adducts are formed under thermal 25 
conditions. However, steric hindrance is of importance to 
control the approach of the alkenes towards the nitrones. 
Operating under metal-catalysed or organocatalysed 
processes, run at lower temperatures, the overall control of the 
absolute configuration of each stereogenic centre can be 30 
achieved. The diastereoselective processes are also efficient to 
furnish optically enriched heterocycles.7d  
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 This cycloaddition has been applied (in lesser extension 
than the above mentioned azides) to the elaboration of 
inhibitors of RNA viral strands. For example, it was found 
that derivatives of natural nucleic acids play an important role 40 
in current chemotherapy as potent and selective antiviral 
agents in AIDS treatment. The ribose ring surrogates depicted 
on Figure 7 are considered as active inhibitors of HIV. 
Especially active was product ADF 37, which was a good 
inducer of cell death by apoptosis on Molt-3-cells, a 45 
continuous line of human thymphoblasts.49 In previous works 
some isoxazolidines 31-35 (also called aza-
dideoxynucleosides) were synthesized through the same route 
with identical objective, but the inhibition of HIV was only 
moderate.50,51,52,53 In all cases, products 31-37 were obtained 50 
through the 1,3-DC of the nitrone with the corresponding N-
vinylpurine or N-vinylpyrimidine heating the mixture for 4 h 
approximately, obtaining only the desired regioisomer. 
Azanucleosides can act as intercaling drugs avoiding the 
reverse transcription or can induce a different new double-55 
stranded RNA (dsRNA), which effectively inhibit the 
expression of the HIV genes. 
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 The herpes simplex virus (HSV) type 1 and 2 are very 
extended viruses causing different pathologies. The inhibition 65 
of them can be achieved by the use of molecule 38a (B = 5-
fluorouracyl) rather than other isoxazolic nucleosidic bases 38 
(Figure 8). Again, N-vinylpurines or N-vinylpyrimidines were 
employed as dipolarophiles.54 Bicyclic N,O-nucleoside 
analogues 39 showed an interesting inhibition of HSV-1 70 
replication in the range of 100 μM. The particular 
conformation of 39 reduces the probability of puckering 
interconversion, which justify strongly the conserved DNA-
like shape and therefore they could be considered for 
optimisation studies for designing more potent HCV reverse 75 
transcriptase inhibitors.55 Phosphonated carboxylic-2’-oxa-3’-
azanucleosides 40 were obtained according to the already 
mentioned thermal 1,3-DC. The nitrone-phosphonate and 
vinyl acetate followed by the attack of the purine or 
pyrimidine moiety to the anomeric carbon. The resulting 80 
nucleosidic derivatives 40 were tested and low levels of 
cytotoxicity were detected, but most importantly was their 
activity as inhibitors of reverse transcriptase in virus. In fact, 
it was as powerful as AZT and one of the most effective 
known inhibitors of the hepatitis B virus.56 The ability of the 85 
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newly synthesized compounds to inhibit retroviral RNA-
dependent DNA polymerase (reverse transcriptase) activity 
was determined by means of a novel, cell-free assay, 
originally developed for a preliminary screening of potential 
inhibitors of reverse transcriptase. In this assay, RNA isolated 5 
from stable transfectants, expressing constitutively the 
glycoprotein D (gD) of HSV-1, was used as template for the 
reversal transcriptase activity of commercial avian 
myeloblastosis virus reverse transcriptase (AMV-RT) and 
moloney murine leukemia virus reverse transcriptase (MLV-10 
RT).56  The postulated mechanism of the inhibition of the 
reverse transcriptase was identical to the already described for 
AZT surrogates (above).  
 The homologous series of azanucleosides 41 were prepared 
by the same chemical route but using a microwave radiation 15 
(100 W, 20 min) for the obtention of a 1.8:1 endo:exo ratio of 
the precursor isoxazoline in 65% yield. Their activity as 
inhibitors of HIV or HBV was moderate and lower than 
homologous structures 40. However, compounds 41 
contributed to the research of the structural features, which 20 
concur to determine the biological activity of the N,O-
nucleoside system.  
 The insertion of nucleotides in the growing nucleic acid 
chain, operated by polymerases, is assisted by bivalent 
metallic ions that facilitate the transfer of nucleotide units. It 25 
was speculated that the nitrogen atom of the heterocycle 
would facilitate the breaking between Pα and Pβ in the 
nucleotide triphosphate structure and, in this way, allows the 
transfer of a diphosphoryl or a nucleotidyl group. The 
nitrogen atom is probably responsible for metal-ion 30 
coordinations and, in this context, while the distance Pα-N3 in 
compounds 40 promotes the formation of 6-membered 
chelates, for compounds 41 the distance Pα-N3 is not 
compatible with anyone stable 7-membered chelate and, 
consequently, any antiviral activity is forbidden.57 35 
 Compound 42, obtained by reaction of the corresponding 
nitrone and allyl alcohol at 160 ºC, was active against the 
bunyavirus punta toro virus (PTV) for which 
cytotoxic/antiviral ratio was virtually 10-fold. This PTV is 
one of eight members of the family Bunyaviridae, which 40 
produce disease in man through accelerated apoptosis of 
hepatocytes in vivo. Preliminary docking studies of this 
compound 42 to the B-DNA fragment d(CGCAATTGCG)2 
show that it preferentially intercalates in the DNA AT region, 
and the resulting complex is further stabilised by a hydrogen 45 
bond between the hydroxyl group of the hydroxymethyl 
moiety and an oxygen of a phosphate group.58 
 Whilst potentially inhibitors of virus endo- and exo-43 are 
currently being evaluated in vivo,59 the formation of isoxazole 
44 was the key step in the total synthesis of racemic BCX-50 
1812(RWJ-270201) 45. The 1,3-DC was performed at room 
temperature in the presence of sodium hypochlorite with an 
isolated yield of 61%. Compound 45 is in clinical phase due 
to its notable selectivity and potency against neuraminidase of 
a wide range of influenza A and B viruses. The strong 55 
interaction between 45 and the S2 region of neuraminidase 
ensures a high inhibition. However, this agent may not confer 
ideal therapeutic characteristics due to several side effects. 
The establishment of a practical, efficient, and versatile 
synthetic route would contribute to further structure-activity 60 
relationship (SAR) studies needed for the development of safe 
and potent neuraminidase inhibitors.60 
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Figure 8. Thermally-generated isoxazolines with noticeable 65 
inhibition of different virus types. 
 
 The diastereoselective synthesis of N,O-nucleosides 48 was 
achieved in 41% yield by the reaction of intermediate nitrone 
47, obtained from N-ribosylhydroxylamine 46, with N-70 
vinylpurines or N-vinylpyrimidines. The diastereomeric ratios 
were moderate (1.5:1) furnishing compound 48a as major 
stereoisomer (Scheme 6). Nucleoside analogues 48 exhibited 
low levels of cytotoxicity, however, heterocycles 49a and 49b 
(base = fluorouracil, FU) caused very fast cell death by 75 
apoptosis in lymphoid cells. These investigations opened new 
perspectives on their possible use as therapeutic antiviral 
agents. To obtain further information on the mechanisms 
regulated by AdFU-induced apoptosis, the possible 
involvement of the caspase-cascade was confirmed after 80 
culture tests and calorimetric assays.61  
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Scheme 6. Synthesis of antiviral compounds 48 and 49. 
 
 
4. Azomethine ylides 5 
 
Azomethine ylides are 1,3-dipoles very frequently generated 
in situ, by a thermal 1,2-prototropy shift in iminoesters 50 or 
by a base-assisted formation of a metallo-dipole also from 50. 
Although many other methods are known, the metallo-dipole 10 
route is the most employed due to its simplicity and the 
mildness of the reaction conditions required.7,62 According to 
the stereochemical point of view, metallo-dipoles 52 are 
crucial species because its geometry is perfectly controlled, 
which allows to obtain highly diastereoselective 1,5-cis-15 
adducts. The frontier orbital theory (FOT) explains the high 
regioselectivity and very important endo/exo 
diastereoselections achieved in the preparation of proline 
derivatives 5363 (Scheme 7), following the identical dipole-
dipolarophile approach depicted for nitrones (see Scheme 5). 20 
All this features are a solid support to catalytic 
enantioselective processes64 determining unambiguously the 
absolute configuration of up to four stereogenic centres of 
pyrrolidines 53.65 The 1,3-DC using azomethine ylides is only 
productive when electron-deficient alkenes are employed. 25 
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Scheme 7. General 1,3-DC using azomethine ylides. 
 
 One of the most relevant applications of these 30 
cycloadditions is the generation of the key intermediate in the 
preparation of potent and promising inhibitors of the HCV 
polymerase. This enveloped single-stranded RNA virus 
(belonging to the Flaviviridae family) is present in six major 
genotypes in the world industrialized nations, genotype 1 35 
being the most prevalent, followed by genotype 2 and 3. 
Inside of the infected hepatocyte, structural E1 and E2 and 
non-structural proteins such as NS2, NS3 (which bears serine 
proteinase, helicase, and NTPase activities), NS4A, NS4B, 
NS5A (regulators of RNA replication), and NS5B (the RNA-40 
dependent RNA polymerase) are generated.66,67 So, their high 
replication rates (billions of copies per day) can be drastically 
suppressed by the inhibition of the NS5B RNA-dependent 
RNA polymerase enzyme, which is the primary target for oral 
antiviral agents 54− 57 (Figure 9).68 45 
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Figure 9. Proline inhibitors of the HCV. 
 
 The preparation of racemic N-acylpyrrolidine 54 was 50 
accomplished by means of concerted thermal 1,3-DC between 
 This journal is © The Royal Society of Chemistry [year] Journal Name, [year], [vol], 00–00  |  9 
supported Wang resin-azomethine ylides 58 and tert-butyl 
acrylate (Scheme 8). The pure enantiomers were separated by 
preparative chiral HPLC, after amidation and hydrolysis of 
both esters groups.69 In this way, many N-acyl pyrrolidines 
were designed finding heterocyclic compound 57 as the most 5 
promising candidate to help infected people.  
 The potent activity of these series of products was 
correlated with the binding site identification and genotypic 
profiling of HCV polymerase inhibitors.70 The search for 
hepatitis C virus polymerase inhibitors has resulted in the 10 
discovery of several non-nucleoside binding pockets. The 
shape and nature of these binding sites differ across and even 
within diverse hepatitis C genotypes. These differences 
confront antiviral drug discovery with the challenge of 
binding compounds that are capable of inhibition in variable 15 
binding pockets. It was demonstrated that the recombinant 
P495L, M423T, M414T, and S282T mutant enzymes could be 
used to identify the binding site of the acyl pyrrolidine 
inhibitors. For these prolines it was found that Phe415 is 
crucial for genotype 1a coverage. Hydrogen bonding and 20 
contacts with the polypeptide backbone are rare. To best adapt 
to highly variable binding sites of NS5B, small molecules 
ideally used hydrophobic interactions with the residue placed 
at the α-position of the heterocycle. The hydrophobic 
arilcarbonyl group must be important in order to ensure or 25 
increase the permeability through the lipidic membranes. This 
property is transformed in good replicon potency and good 
pharmaco-kinetics for future developments of new drugs. The 
α-epimers are more potent than the corresponding β-
epimers.70  30 
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Scheme 8. Synthesis of the racemic endo-54 
 35 
 The first synthesis of racemic product 55, and another 
derivatives including compound 54 was achieved in several 
steps using as the key reaction the silver(I) or lithium-
metalloazomethine ylide, generated from iminoester 60 under 
basic conditions and tert-butyl acrylate. The resulting 40 
cycloadduct 61 was obtained in 67% yield through a non-
concerted mechanism (Scheme 9). The enantiomeric samples 
were isolated from semi-preparative chiral HPLC. A small 
modification on the side chain of the heterocycle (amido 
group instead of carboxylic group) gave raise to product 62, 45 
which in its (+)-form exhibited superior activity in both the 
enzyme and the replicon assays (Scheme 9).71  
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Scheme 9. Synthesis of several racemic HCV inhibitors. 50 
 
 Molecule 56 (3082) was obtained through the analogous 
key intermediate 61 (Scheme 9). These 3-methoxyarylamides 
had superior solubility properties and lower molecular weights 
than other precedent antiviral agents. In this occasion, to 55 
resolve the racemic mixtures of compound 61, (R)-(−)-1,1’-
binaphthyl-2,2’-diyl-hydrogen phosphate was employed 
providing the required diastereomeric salt in good yield and 
excellent enantiomeric excess at the end of the process 
(98.8%). In this work, a comparison of the X-ray structures of 60 
dicarboxylic acid 55 and the binding site of the HCV 
polymerase was surveyed. The bulkier tert-butyl substituent 
on the benzamide caused movement in the side chain of 
Leu384 allowing inhibitors to bind deeper into the pocket an 
increase their antiviral power.72 This result was in total 65 
agreement with those previously reported (see above).   
 The first endo-diastereoselective 1,3-DC of the key 
precursors of these antiviral agents was achieved via silver(I)-
metalloazomethine ylide in the presence of acrylates derived 
from (R)- or (S)-methyl lactate 64. The diastereoselection was 70 
very high (96% de) and 77% of chemical yield. 
Enantiomerically enriched (+)-54 and (−)-54 forms were 
finally isolated in 96% ee and in 51-54% yield (overall yield 
from iminoester 63), after successive amidation and double 
hydrolytic process. In spite of the small size of the 75 
substituents bonded around the stereogenic centre, it was 
demonstrated that the excellent stereocontrol was originated 
by the interaction of the lactate methyl groups and the phenyl 
residue of the starting iminoester.73  
 80 
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 The more straightforward and faster approach to the 5 
enantiomeric forms of these non-nucleosidic antiviral agents 
is based on a catalytic enantioselective 1,3-DC as the key 
step.64 The asymmetric reaction was pioneered by Grigg and 
coworkers in 1991 using stoichimetric amounts of chiral bases 
or chiral metal complexes.74 However, it was in 2002 just 10 
when the first substoichiometric catalytic (3 mol%) 
enantioselective transformation was successfully reported by 
Zhang and coworkers using a chiral diphosphane/silver(I) 
complex.75 At that time, this cycloaddition became a 
fascinating transformation and many contributions appeared 15 
with outstanding results. Chiral metal complexes, chiral bases, 
and chiral organocatalysts have been tested obtaining the best 
results, in terms of diastereo- and enantioselectivities, and 
wider general scope when chiral metallodipoles were 
generated as intermediate products. Silver(I)76 and copper(I)77 20 
catalytic complexes afforded the most efficient and attractive 
processes.78,79  
 The first enantioselective synthesis of the five-membered 
core of these structures was performed by using a chiral 
phosphoramidite 67 and AgClO4 (both in 5 mol% amounts) as 25 
catalyst. The reaction run at −20 ºC furnishes a good yield of 
compound endo-66 with a high enantioselection (Scheme 11, 
and Table 1, entry 1). In this work, the synthesis of 
enantiomerically enriched product 54 (82% ee) was also 
reported after amidation and double hydrolytic sequence 30 
involving TFA/0 ºC followed by KOH-MeOH/80 ºC.76j,80 Box 
ligand 68 and calcium isopropoxide formed a chiral complex, 
which was used to catalyse the process at −44 or −30 ºC in 
THF as solvent. The yields are high and the 
enantioselectivities are the highest reported to date for 35 
compound 66 (85 and 88% ee) (Scheme 11 and Table 1, 
entries 2 and 3).78d Apart from the Lewis acid-catalysed 1,3-
DC the concept of organocatalysis was applied to the 
synthesis of 66 using hydroquinine 69 as quiral base (6 mol%) 
together with a 3 mol% amount of silver acetate. Although 40 
chemical yields were very important, the enantioselection was 
moderate (74% ee) (Scheme 11, and Table 1, entry 4). In fact, 
a further 1,1’-binaphthyl-2,2’-dihydrogen phosphate asisted 
chiral resolution of 66 was performed in order to obtain pure 
compound endo-66 with a 99.8% ee.79g  45 
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Table 1. Catalytic enantioselective synthesis of compound 66. 50 
X R1 R2 Salta La Basea T(ºC) Yield (%)b ee (%)
CH Me But 
AgClO4 
(5) 
67 
(5) 
Et3N 
(5) 
−20 70 82 
CH But But 
Ca(OPri)4 
(10) 
68 
(10) 
___ −44 83 85c 
N But But 
Ca(OPri)4 
(10) 
68 
(10) 
___ −30 83 88c 
N But Me 
AgOAc 
(3) 
69 
(6) 
___ 0 or −10 84 74 
a In brackets (x, y or z mol%). b Isolated yield. c ent-66 was obtained. 
 
 To the best of our knowledge the synthesis of antiviral 
agent 57 has not been reported yet,81 and it appeared as a 
consequence of evolutive structural modifications of the 55 
precedent inhibitors, namely potency of the molecule, cell 
penetration and pharmacokinetics. Product 57 (GSK625433) 
is the most potent and selective drug having a good 
pharmacokinetic profile in phases I and II. This last 
compound does not inhibit human DNA polymerases, can be 60 
administrated in low concentrations and no significant 
cytotoxicity was observed.82 The discovery of the active 
specific interaction site polymerase-receptor for the inhibitors 
supports this new trend of therapy. A small modification in 
the final structure of 57 can be translated in a more potent 65 
inhibition of the named viral polymerase, the highest optical 
purity of intermediate 66 being modulated by selecting the 
most appropriate solvent, silver salt, chiral ligand, 
temperature, and base. 
 This alternative therapy is orally administrated in smaller 70 
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amounts, it is more inexpensive and causes much less side 
effects and complications than the current subcutaneous 
pegylated α-interferon treatment combined with oral ribavirin. 
In addition, RNA-polymerase inhibition is much more 
effective than the inhibition of other structural and non-5 
structural viral proteins in the fight against HCV. 
 
 
5. Nitrile oxides 
 10 
Similarly to azomethine ylides, nitrile oxides 71 have to be 
generated in situ. There are many methods described for their 
preparation,7d dehydrohalogenation of hydroxymoyl chlorides 
70 and dehydration of nitroalkanes being the most frequently 
used strategies. The regioselectivity of the 1,3-DC of nitrile 15 
oxides and alkenes or alkynes is easily predictable. For 
monosubstituted alkenes and electrophilic olefins major 
regioisomer isoxazoles or isoxazolines48 72a and 72b are, 
respectively, isolated as pure compounds (Scheme 12). At 
maximum, only two stereogenic centres can be generated 20 
employing catalytic enantioselective synthesis. 
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Scheme 12. Synthesis of the major regioisomers 72. 
 25 
 As well as it was described previously for azides, nitrile 
oxides are used to strategically modify several parts of the 
molecule with the aim to increase its antiviral potency. Initial 
contributions were designed for studying the antiviral activity 
of a series of products, but any biological results of essays 30 
was detailed.83 That was the case of C-nucleoside analogues 
7384, and isoxazolines 7485 (Figure 10), which were obtained 
following the conditions depicted on Scheme 12 but using an 
α-bromoacrylic system.86 They have a potential activity 
against varicella-Zoster virus (VZV), cytomegalovirus 35 
(CMV), and herpes simplex virus (HSV). Particularly, 
compound 73, obtained from N-vinylpurines, was moderately 
effective against HIV-1 in acutely infected primary human 
lymphocytes.84 N-Oxide carbonocyanidic acid ethyl ester 
reacted with benzodiazepines to yield compounds 75 that are 40 
considered as HIV reverse transcriptase inhibitors.87 N-
Adamanthyl isoxazoline 76 is a very simple structure that 
showed a slight inhibition of HIV.88 Since this publication, 
several articles reported modified structures able to hamper 
the development of HIV. For example, nucleoside and 45 
nucleotides 77 and 78 (n = 1) (Figure 10) were obtained from 
the nitrile oxide and the corresponding N-vinylnucleo-base. 
The results were very promising against HIV, 78 (n = 1) being 
the most effective and less cytotoxic drug.89 The connection of 
oxygen and nitrogen atoms provided a possibility to introduce  50 
the nucleophilic nitrogen into the furanose ring with a 
minimum of steric manipulation, providing opportunities to 
modify the furanose ring of  nucleoside analogues with novel 
structural features. Consequently, it became possible to design 
other related N,O-containing derivatives for biological 55 
studies. 
 However, homologue compounds 78 (n = 0) (Base = 
thymine, fluorouracil, or cytosine) and 79 (Base = thymine) 
(Figure 10) completely inhibited the reverse transcriptase 
activity of the avian myeloblastosis retrovirus at 10 μM 60 
concentration. These isoxazolines 78, and 79 exhibited lower 
potency with respect to isoxazolidine derivatives 40, and 41 
(Figure 8).90 The lesser ability to elicit recognition by the 
reverse transcriptase, due to the insertion of a double bond in 
the five-membered heterocycle, can be attributed to a lower 65 
molecular flexibility and a lower basicity of the nitrogen 
atom. Such as it was already mentioned, the bivalent metallic 
ions assisted the insertion of nucleotides in the growing 
nucleic acid chain. In this particular case, Mg+2 could form a 
six-membered chelate with the nitrogen atom and the oxygen 70 
of the phosphorous group as well.90 
 The 1,3-DC involving nitrile oxides and alkynes (methyl 
propiolate) was studied in the generation of isoxazoles and 
isothiazoles 80 and 81, respectively. These aryl-substituted 
heteroaromatic carboxylic acids (when R = 3-BnO in 80, and 75 
R = 4-NO2 in 81) afforded advantageous features of 
improvement of antiviral potency against HIV-1 integrase and 
decreased cytotoxicity with high therapeutic index. The good 
antiviral potency of the heteroaromatic carboxylic acid series 
could be attributable to the improved bioavailability of the 80 
bioisosteres. On the other hand, the inconsistency between 
integrase inhibitory activity and the antiviral effect might 
involved multiple targeting in the HIV-1 life cycle.91 
   Finally, 2-deoxyuridine derivatives 82 (Figure 10), formed 
by 1,3-DC of nitrile oxides and 5-alkynyluridines showed a 85 
poor affinity for HSV-1-specific thymidine kinase.92,93 
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6. Diazoalkanes and carbonyl ylides 5 
 
For a long time diazo-compounds 83 have been one of the 
most synthetically useful classes of 1,3-dipoles because they 
could be prepared and isolated in pure form in contrast o 
another 1,3-dipoles that are generated as transient species.7d 10 
The cycloadditions with double or triple bonds (including 
heteroatoms) have been widely surveyed (Scheme 13).7 The 
reaction with electrophilic olefins occurred such as it is 
depicted in Scheme 13, the carbon atom reacted at the 4-
position of the electrophile with almost total selectivity to 15 
yield pyrazoline or pyrazole derivatives 84 and 85, 
nevertheless, some mixtures are obtained by reaction with 
electron-rich alkenes. In addition, the reaction of diazoalkanes 
with nitriles also give good regioselectivities of the 
corresponding compounds 85 (Scheme 13). 20 
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Scheme 13. General 1,3-DC promoted by diazoalkanes 
 
 The commercially available diazo(trimethylsilyl)methane is 25 
a safe, non-explosive and non-mutagenic substitute of 
diazomethane, and its cycloaddition can be greatly expanded 
by metallation with butyllithium. In general, Δ1-pyrazolines or 
pyrazoles 84 or 8594 were regioselectively obtained at very 
low or room temperature (Scheme 13). In some occasions, the 30 
five membered ring is not the active substance but the 
corresponding cyclopropane, generated via photoinduced 
elimination of molecular nitrogen. 
 Thus, 2’,3’-dideoxy-2’,3’-α-methanocytidine 88 was 
prepared following this last mentioned sequence where the 35 
key intermediate 87 was regioselectively obtained in 84% 
yield and almost total diastereoselection. Product 88 only 
exhibited weak to moderate activity against the HIV95 
(Scheme 14). 
 40 
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Scheme 14. Synthesis of antiviral agents 87 and 88. 
 
 Δ1-Pyrazoline 90 was diastereoselectively obtained (>99:1 
dr) in quantitative yield. This heterocycle was aromatised to 45 
yield the corresponding pyrazole unit with some interesting 
weak inhibition of several types of viruses (Scheme 15).96  
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Scheme 15. Synthesis of heteocycle 90. 50 
 
 The synthesis of pyrazole-5-carboxamide 95 started with 
the 1,3-DC between 1-(diazomethyl)-D-allitol derivative 92 
and butynoate 93. Compound 94 underwent very simple and 
standard reaction transformations to yield finally carboxamide 55 
95 (Scheme 16). Analogously, amide 96, possessing the 
truncated acyclic side chain of acyclovir, was prepared in a 
similar manner. Both pyrazoles 95 and 96 demonstrated a 
weak biological activity against HIV, yellow fever virus, and 
vaccine virus.97 60 
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 Diazo-compounds 98 were allowed to react with coumarins 
97, bearing a nitrile functional group, yielding products 99 in 5 
very good yields (73-85%). After several steps coumarins 100 
and the analogous adducts 101 were isolated. Compounds 101 
showed encouraging results by inhibition of HIV-1 with an 
IC50 value >0.17 μM, whilst none of the tested compounds 
100 was found to inhibit HIV-1 or HIV-2 replication. The 10 
structure-activity relationship (SAR) suggested that molecules 
incorporating the carbon-coumarin linkage manifested a 
higher HIV inhibition activity than that of the corresponding 
analogues having the oxygen linkage as structures 100.98 
These results would lead to modify the target molecules by 15 
the introduction of more potential groups with a carbon 
linkage. 
 
 
OO
R1
O
N
97
N
N
R2Cl
R3
R4 R5
+ SbCl4
_
(73-85%)
98
OO
R1
O
99
N
NH
N
R4
R5
Cl
R2
R3
OO
R1
O
N
N
N
R4 R5
100
OO
OMe
N
N
N
R1
101
R2
 20 
Scheme 17. Synthesis of series of compounds 100 and 101. 
 
 To the best of our knowledge only one example of 
compounds with antiviral activity was published employing a 
1,3-DC between in situ generated carbonyl ylides and alkenes. 25 
In this work tetrahydrofuranyl glycine 104 have been obtained 
in 65% yield from L-vinylglycine 102 through a 1,3-DC 
reaction using the non-stabilised carbonyl ylide, prepared 
from carcinogenic bis(chloromethyl) ether 103. The reaction 
was run at 0 ºC achieving better chemical yield of a 57:43 30 
mixture of diastereoisomers (Scheme 18).99 The resulting 
polypeptides, incorporating this α-amino acid 104, acted as 
substrate-based inhibitors of HIV-1 protease. The inhibitory 
action of these macromolecules was probably due to the 
favourable interactions at the S2 region of neuraminidase (see 35 
above). This strategy proved to be very valuable to medicinal 
and peptide chemistry due to the numerous modifications to 
essay.  
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Scheme 18. 1,3-DC involving a carbonyl ylide as 1,3-dipole. 
 
 
7. Conclusions 
 45 
 After more than a century after their discovery, these 1,3-
DCs represent a powerful tool in modern synthetic chemistry 
whose limits are still being explored. According to the 
previously described contents and in the search of drugs with 
the wider spectrum of activity, a clear perspective can be 50 
defined: the 1,3-DCs allow structural simple modifications, 
which fits to Lipinki’s rules, facilitating the interaction drug-
virus at different stages. Ylides are easily generated, the 
reactions involved are highly regio- and diastereoselective, 
even with elevated enantioselection for enantioselective 55 
processes. The reaction conditions are usually very mild and 
the atom economy is almost total. Azides, nitrones, and 
azomethine ylides are the most employed dipoles giving rise 
to nitrogenated five membered ring heterocycles. Particularly 
interesting is the enantioselective approach to them using 60 
substoichiometric amounts of chiral catalysts. 
 The most promising methodology is based on the 
azomethine ylide and its reactions with alkenes. In fact, this 
cycloaddition is a light of hope for the more of 190 million 
people having chronical hepatitis C in the world. This 65 
asymmetric reaction would allow to prepare multiple libraries 
of chiral molecules able to inhibit the HCV replication. The 
scope of these products can be also applied to the single or 
combined treatment of the HIV/HCV coinfected people (15 
million of patients in a critical situation) or for the treatment 70 
of influenza or other devastating viruses, however, we have 
not any data about all these ambitious goals. 
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